| Literature DB >> 22835455 |
Mary E Choi1, Yan Ding, Sung Il Kim.
Abstract
In progressive kidney diseases, fibrosis represents the common pathway to end-stage kidney failure. Transforming growth factor-β1 (TGF-β1) is a pleiotropic cytokine that has been established as a central mediator of kidney fibrosis. Emerging evidence shows a complex scheme of signaling networks that enable multifunctionality of TGF-β1 actions. Specific targeting of the TGF-β signaling pathway is seemingly critical and an attractive molecular therapeutic strategy. TGF-β1 signals through the interaction of type I and type II receptors to activate distinct intracellular pathways involving the Smad and the non-Smad. The Smad signaling axis is known as the canonical pathway induced by TGF-β1. Importantly, recent investigations have shown that TGF-β1 also induces various non-Smad signaling pathways. In this review, we focus on current insights into the mechanism and function of the Smad-independent signaling pathway via TGF-β-activated kinase 1 and its role in mediating the profibrotic effects of TGF-β1.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22835455 PMCID: PMC3407377 DOI: 10.1016/j.semnephrol.2012.04.003
Source DB: PubMed Journal: Semin Nephrol ISSN: 0270-9295 Impact factor: 5.299